July 15, 2024

Polycystic Ovary Syndrome (PCOS) Treatment Market High Growth Opportunities, Emerging Trends, Industry Review, Forecast Till 2030

Market Overview:

Polycystic ovary syndrome (PCOS) is a hormonal disorder common among women of reproductive age. The main symptoms of PCOS include irregular or no menstrual periods, excess androgen, polycystic ovaries and difficulty getting pregnant. PCOS is the most common hormonal disorder among women. The treatment involves medications and lifestyle modifications to manage symptoms such as irregular periods, excess hair growth, acne, weight gain and insulin resistance. Drugs such as oral contraceptives, metformin, and anti-androgens are commonly used to manage PCOS symptoms.

The global Polycystic Ovary Syndrome (PCOS) Treatment Market is estimated to be valued at US$ 1,086.6 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/polycystic-ovarian-syndrome-treatment-market-1589

Market key trends:

One of the major trends in the PCOS treatment market is increasing research in drug candidates, biomarkers and novel therapeutics. Researchers are striving to develop drugs that can effectively manage PCOS symptoms and prevent its related health complications like diabetes. Several companies are conducting clinical trials on new medications or route of administration of existing therapies. Further, considering the rising economic burden of PCOS worldwide, development of cost-effective therapies remains a major focus area. Diagnostic capabilities are also advancing with novel biomarkers being identified for early detection and personalized treatment of PCOS.

Porter’s Analysis

Threat of new entrants: Low barrier to entry since the market is fragmented in nature and there are many regional players. However, established players have strong brand recognition and distribution networks.

Bargaining power of buyers: Moderate as many generic drugs are available for treatment. Buyers can negotiate on price.

Bargaining power of suppliers: Low since raw materials for manufacturing drugs are easily available.

Threat of new substitutes: Moderate threat from alternative treatment options like lifestyle changes, supplements etc.

Competitive rivalry: High due to presence of many regional and global players offering generic versions at lower prices.

Key Takeaways

The global Polycystic Ovary Syndrome (PCOS) Treatment Market is expected to witness high growth, exhibiting CAGR of 4.8% over the forecast period, due to increasing prevalence of PCOS and rising awareness about its treatment.

The North America region is expected to dominate the global PCOS treatment market during the forecast years owing to the increasing prevalence of PCOS, rising healthcare spending, and growth in healthcare awareness. Asia Pacific region is anticipated to exhibit the fastest growth rate over the forecast period due to the rising awareness about lifestyle-related disorders and growth in medical tourism industry.

Key players operating in the Polycystic Ovary Syndrome (PCOS) Treatment market are Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy’s Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., and Covis Pharmaceuticals, Inc. Sanofi S.A. is one of the leading players owing to its strong portfolio of medicines for PCOS treatment.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it